Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.50 and traded as low as $0.41. Elite Pharmaceuticals shares last traded at $0.42, with a volume of 807,140 shares traded.
Elite Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.12, a current ratio of 3.27 and a quick ratio of 1.90. The stock has a market capitalization of $468.58 million, a PE ratio of -21.93 and a beta of 0.04. The stock has a 50 day moving average of $0.43 and a two-hundred day moving average of $0.50.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last issued its earnings results on Thursday, February 13th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter. Elite Pharmaceuticals had a negative return on equity of 6.92% and a negative net margin of 25.70%.
Elite Pharmaceuticals Company Profile
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
See Also
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
